Loading…
← CockpitCompetitor Analysis › 600380.SS Joincare Pharmaceutical Group Industry Co., Ltd. Class AOpen in the cockpit ↗

Joincare Pharmaceutical Group Industry Co., Ltd. Class A600380.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese pharmaceutical and health-products conglomerate (Haiwang brand) spanning generics, nutraceuticals and pharmacy retail.

Momentum leader 93
Mkt cap
$2.85B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$24.7M
20-day average traded
Fwd P/E
15.5×
forward earnings
ROIC−WACC
+4.2 pp
WACC 5.0%
Hurdle
-15 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥10.53
1D+0.5%
1W+2.7%
1M+11.9%
3M+1.7%
6M+0.4%
YTD-8.8%
1Y-12.5%
ATR %2.2%
52w lowhigh18.1% off high

What Joincare Pharmaceutical Group Industry does

Chinese pharmaceutical and health-products conglomerate (Haiwang brand) spanning generics, nutraceuticals and pharmacy retail.

Sells prescription drugs to hospitals, largely through Livzon Pharmaceutical Group, a separately listed drugmaker it controls, and sells nutraceuticals and health products to consumers through pharmacies and retail channels under its Haiwang brand. Livzon's own shares trade separately in Shenzhen and Hong Kong.

Products and services

  • Generic pharmaceuticals
  • Nutraceuticals/health products (Haiwang brand)
  • Pharmacy retail

Customers

  • Hospitals
  • Retail consumers

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Generics + nutraceuticals + pharmacy…

What could go right

  • Health/nutraceutical consumer demand growth

What could go wrong

  • Centralized procurement price pressure
  • Diversification dilutes margins

Moat: narrow (brand, distribution). Established Haiwang consumer brand plus a diversified generics/retail distribution network.

Headquarters: Shenzhen, China · Employees: 13,575

Named competitors

Joincare Pharmaceutical Group Industry at a glance

Size Joincare Pharmaceutical Group Industry (600380.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.85B, the 845th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.53 on 18 Nov 2026.

Performance Over six months the shares gained 0.4%, against -9.7% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue fell 11.8% over the last twelve months (peer median +14.8%); the operating margin is 17.6% (peer median 12.0%).

Valuation It trades at 15.5× forward earnings against a peer median of 27.1× (4th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -15 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.2 points above its cost of capital (5.0% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026600380.SS 103Peer median 89
Six months, rebased to 100: Joincare Pharmaceutical Group Industry against the median of its 20 peers (local-currency closes).

Joincare Pharmaceutical Group Industry financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥13.4BCN¥15.1BCN¥15.5BCN¥16.5BCN¥17.0B
Revenue growth—-3%-6%-3%—
Gross profitCN¥8.38BCN¥9.12BCN¥9.40BCN¥9.65BCN¥10.4B
EBITDAn/aCN¥3.89BCN¥4.17BCN¥4.28BCN¥4.08B
Net incomeCN¥1.13BCN¥1.34BCN¥1.39BCN¥1.44BCN¥1.50B
Free cash flowCN¥3.04BCN¥3.16BCN¥2.68BCN¥2.95BCN¥2.97B
Capital expenditureCN¥709MCN¥767MCN¥979MCN¥1.13BCN¥1.15B
Total debtCN¥5.80BCN¥5.50BCN¥6.68BCN¥7.40BCN¥7.08B

Quarterly statements and history in the cockpit →

Joincare Pharmaceutical Group Industry competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%NEULANDLAB0867002773VCEL3005583001992696BIOA-BACAD600518LEGN688266IDYA600535600511301301ALMVKTX000739PBH600380.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Joincare Pharmaceutical Group Industry is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%20×40×60×NEULANDLAB0867002773VCEL3005583001992696BIOA-BACADLEGN688266600535600511301301ALM000739600380.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Joincare Pharmaceutical Group Industry is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%0867002773VCEL3005583001992696BIOA-BACAD688266600535600511301301ALM600380.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Joincare Pharmaceutical Group Industry is the large dot.

Joincare Pharmaceutical Group Industry competitors and peer comparison

Head to head with its named competitors (600380.SS vs 000999.SZ vs 300146.SZ vs 000538.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Joincare Pharmaceutical Group Industry 600380.SS$2.85B0%-12%18%15.5×-13.1%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
By-health 300146.SZ$2.56B-1%+10%11%24.7×4.8%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
Cspc Pharma 1093.HK$12.0B+10%+25%28%9.1×-10.7%

How Joincare Pharmaceutical Group Industry compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Joincare Pharmaceutical Group Industry against its 20 peers (data as of 18 Nov 2026)
Measure600380.SSPeer medianRank in peer set
1-month return+11.9%-1.4%2nd highest of 21
6-month return+0.4%-9.7%6th highest of 21
Distance from 52-week high-18.1%-38.0%6th highest of 21
Revenue growth (TTM)-11.8%+14.8%5th lowest of 20
Operating margin17.6%12.0%9th highest of 20
Forward P/E15.5×27.1×4th cheapest of 18
Growth the price implies (Req g, 7 yrs)-13.1%6.1%least demanding of 16
Growth delivered (Del g)+2.4%+6.5%2nd lowest of 16
Hurdle (Req g minus delivered)-15.5 pp-1.3 pp4th least demanding of 16
ROIC minus cost of capital+4.2 pp+1.2 pp7th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%

Questions

Who are Joincare Pharmaceutical Group Industry's main competitors?
Named competitors: China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), By-health (300146.SZ), Yunnan Baiyao (000538.SZ), CSPC Pharmaceutical Group (1093.HK). The cockpit's measured peer set (industry) also includes Neuland Laboratories (NEULANDLAB.NS), China Medical System (0867.HK), Chengdu Kanghong Pharmaceutical (002773.SZ), Vericel (VCEL), Betta Pharmaceuticals (300558.SZ), Hybio Pharmaceutical (300199.SZ).
Is Joincare Pharmaceutical Group Industry expensive compared with its peers?
On forward p/e it trades at 15.5× against a peer median of 27.1×, 4th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -15 pp: the price already allows for a slowdown.
How has Joincare Pharmaceutical Group Industry stock performed?
Over six months to 18 Nov 2026 the shares returned +0.4% against -9.7% for the median peer; over one year -12.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.